Presenting at ACTRIMS 2025, researchers assessed whether biological aging, measured by metabolomic aging, can be reversed through fasting-mimicking diets in patients with multiple sclerosis.
News
Presenting at ACTRIMS 2025, researchers characterized demographic, socioeconomic, and clinical factors and outcomes in patients with multiple sclerosis with depression and anxiety.
In a retrospective study, researchers assessed the incidence of mild cognitive impairment and Alzheimer disease in patients with MS.
In an interim analysis of ENLIGHTEN, researchers described changes in cognitive function over 1 year in patients with MS.
Presenting at ACTRIMS 2025, researchers reported 4-year health-related quality of life and cognitive function data from patients with relapsing multiple sclerosis from the CLARIFY-MS Extension study.
Presenting at ACTRIMS 2025, researchers assessed the timing of meningococcal vaccination in patients from the CHAMPION-NMOSD trial transitioning from rituximab to ravulizumab.
Presenting at ACTRIMS 2025, researchers reported on the safety and clinical efficacy over 24 months of patients with relapsing multiple sclerosis switching to cladribine from natalizumab.
Presenting at ACTRIMS 2025, researchers determined whether telomere length as a biological aging marker varied among patients with pediatric-onset MS compared with age-similar healthy control individuals.
Presenting at ACTRIMS 2025, researchers analyzed disease activity via MRI and blood biomarkers in Black and Hispanic patients with multiple sclerosis after 96 weeks of ocrelizumab treatment during the CHIMES trial.
Presenting at ACTRIMS 2025, researchers described the association of ocrelizumab concentration with safety and efficacy outcomes in patients with relapsing multiple sclerosis treated with ocrelizumab for up to 10 years.
In a post hoc analysis, researchers assessed the maintenance of the efficacy and safety of transitioning from IV anti-CD20 therapy to ofatumumab by race/ethnicity subgroup in patients with relapsing multiple sclerosis.
Researchers sought to provide data on the safety and tolerability of 30-minute, 450 mg infusions at week 24 in patients with relapsing multiple sclerosis who are a part of the ongoing ENHANCE study.
In an observational, cross-sectional study, researchers assessed the prevalence of sexual dysfunction, depression, and negative health perception, and their relationships with
the Expanded Disability Status Scale (EDSS) in patients with multiple sclerosis.
In a population-based cohort study, researchers estimated the long-term risk of developing multiple sclerosis, and separately, demyelinating diseases, in patients diagnosed with and without Epstein-Barr virus-positive infectious mononucleosis.
Greater prenatal and early childhood sun exposure is associated with a lower risk for relapse among children with multiple sclerosis (MS).
In a multicenter, rater-blinded, noninferiority, randomized clinical trial, researchers assessed whether first-line DMT can be safely discontinued in patients with long-term stable MS.
Worldwide, there have been 82 cases of anaphylaxis reported with glatiramer acetate use since December 1996.
Mothers with multiple sclerosis (MS) have an elevated incidence and prevalence of peripartum mental illness.
The menopausal transition may represent an inflection point for worsening of multiple sclerosis (MS) in women.
Disease-modifying therapy (DMT) use for multiple sclerosis (MS) in pregnancy is associated with certain adverse outcomes.
Researchers compared the effectiveness of cognitive behavioral therapy, modafinil, and their combination in treating fatigue in multiple sclerosis.
Researchers analyzed age-related and disease course-specific cerebrospinal fluid protein signatures in multiple sclerosis using a large-scale targeted proteomic approach.
Nine ICD-10 codes were seen more often in children with multiple sclerosis versus controls without MS.
Researchers conducted a cohort study to determine dynamic functional network trends relevant to cognitive impairment in multiple sclerosis.
Researchers conducted a 10-year nationwide retrospective matched cohort study to compare the risk for cancer in people with multiple sclerosis and a matched sample.
Researchers sought to assess the association of comorbidities with disease activity in clinical trials of disease-modifying therapies in patients with multiple sclerosis.
Presenting at ECTRIMS 2024, researchers identified novel population-specific variants and fine-mapping previously identified multiple sclerosis loci in a diverse ancestral population.
Presenting at ECTRIMS 2024, researchers analyzed the transition from disease-modifying therapy to ublituximab with a modified dosing schedule, and infusion times of less than 1 hour among patients with MS with B-cell depletion.
Presenting at ECTRIMS2024, researchers assessed the effect of cladribine on progression independent of relapse activity, relapse-associated worsening, and confirmed disability accumulation in patients with treatment-naïve and treatment-experienced multiple sclerosis.
Presenting at ECTRIMS 2024, researchers determined the safety and efficacy of tolebrutinib in nonrelapsing secondary progressive multiple sclerosis.
